A Phase 1 Study of ESG206 in Adult Subjects With B-cell Lymphoid Malignancies

NCT05822843 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

13

Enrollment

INDUSTRY

Sponsor class

Conditions

B-cell Lymphoid Malignancies

Interventions

DRUG: ESG206

Sponsor

Shanghai Escugen Biotechnology Co., Ltd